T. Rowe Price Associates’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.6M Buy
92,151
+1,451
+2% +$25.1K ﹤0.01% 1751
2025
Q1
$1.98M Sell
90,700
-267,878
-75% -$5.86M ﹤0.01% 1607
2024
Q4
$11.4M Sell
358,578
-19,878
-5% -$634K ﹤0.01% 1126
2024
Q3
$10.9M Sell
378,456
-897,970
-70% -$25.9M ﹤0.01% 1123
2024
Q2
$49M Sell
1,276,426
-1,182,820
-48% -$45.4M 0.01% 733
2024
Q1
$145M Sell
2,459,246
-1,093
-0% -$64.2K 0.02% 483
2023
Q4
$147M Buy
2,460,339
+677,098
+38% +$40.5M 0.02% 470
2023
Q3
$67.8M Sell
1,783,241
-5,288,985
-75% -$201M 0.01% 590
2023
Q2
$644M Buy
7,072,226
+2,482,186
+54% +$226M 0.09% 215
2023
Q1
$303M Buy
4,590,040
+1,840,498
+67% +$121M 0.05% 312
2022
Q4
$142M Sell
2,749,542
-601,421
-18% -$31.1M 0.02% 435
2022
Q3
$229M Sell
3,350,963
-5,328,850
-61% -$364M 0.04% 338
2022
Q2
$393M Buy
8,679,813
+794,974
+10% +$35.9M 0.05% 335
2022
Q1
$401M Buy
7,884,839
+2,586,348
+49% +$131M 0.04% 370
2021
Q4
$251M Buy
5,298,491
+491,414
+10% +$23.2M 0.02% 499
2021
Q3
$158M Sell
4,807,077
-363,417
-7% -$12M 0.01% 625
2021
Q2
$327M Buy
5,170,494
+1,528,345
+42% +$96.6M 0.03% 438
2021
Q1
$156M Buy
3,642,149
+596,820
+20% +$25.6M 0.02% 629
2020
Q4
$174M Buy
3,045,329
+66,929
+2% +$3.83M 0.02% 558
2020
Q3
$89.9M Sell
2,978,400
-49,435
-2% -$1.49M 0.01% 689
2020
Q2
$98.9M Buy
3,027,835
+1,776,965
+142% +$58M 0.01% 640
2020
Q1
$33.5M Buy
1,250,870
+459,207
+58% +$12.3M 0.01% 910
2019
Q4
$24.2M Sell
791,663
-82,749
-9% -$2.53M ﹤0.01% 1124
2019
Q3
$21.1M Buy
874,412
+175,200
+25% +$4.22M ﹤0.01% 1133
2019
Q2
$17.7M Buy
699,212
+19,324
+3% +$490K ﹤0.01% 1207
2019
Q1
$13.3M Sell
679,888
-38,995
-5% -$760K ﹤0.01% 1275
2018
Q4
$9.48M Sell
718,883
-191,676
-21% -$2.53M ﹤0.01% 1320
2018
Q3
$16.2M Sell
910,559
-51,124
-5% -$909K ﹤0.01% 1286
2018
Q2
$21.2M Buy
+961,683
New +$21.2M ﹤0.01% 1181